

## Data Sharing Statement

Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. DOI: 10.1056/NEJMoa2110345.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual anonymized participant data. See <a href="https://www.pfizer.com/science/clinical-trials/trial-data-and-results">https://www.pfizer.com/science/clinical-trials/trial-data-and-results</a> for more information.
Which data?	—
Additional information about data	—
How or where can the data be obtained?	<a href="https://www.pfizer.com/science/clinical-trials/trial-data-and-results">https://www.pfizer.com/science/clinical-trials/trial-data-and-results</a> . SARS-CoV-2 sequence data may be obtained at <a href="https://www.gisaid.org">https://www.gisaid.org</a> .
When will data availability begin?	Upon request, and subject to review.
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	—
For what type of analysis or purpose?	—
By what mechanism?	—
Any other restrictions?	—
Additional information	—

This statement was posted on September 15, 2021, and updated on September 17, 2021, at NEJM.org.